Avoid off-label use of SGLT2-inhibitors for T1DM, warns TGA
Reports of diabetic ketoacidosis linked to the agents have prompted the regulator to remind doctors of the medicines’ indication
The TGA is urging prescribers to heed warnings against the use of SGLT2 inhibitors for patients with type 1 diabetes because of the increased risk of diabetic ketoacidosis.
In its latest Medicines Safety Update, the TGA reveals that last year it received six reports of SGLT2 inhibitors being used for patients with type 1 diabetes despite the drugs not being approved for this indication.
Three of the reports were adverse events linked to diabetic ketoacidosis (DKA), the regulator said.
“The TGA considers that the seriousness of the risk of DKA requires an updated reminder for prescribers about the risks of off-label use of SGLT2 inhibitors,” the report stated.
